Logo-jre

   
J Ren Endocrinol. 2021;7: e05 | Published on: 2020 Sep 29. doi: 10.34172/jre.2021.05

Original Article

Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program

Anselmo Abdo-Cuza 1 * ORCID, Roberto Castellanos-Gutiérrez 1 ORCID, Janete Treto-Ramirez 1, Sandra Arencibia-Larin 1 ORCID, Thalía Gómez-Pariente 1, Tania González-Fernández 1, Julio C. Hernández-Perera 1 ORCID, Katia Arocha-Stalella 1, Niurka Verdecia-Gorrita 1, Lisy Vento-Buigues 1, Yanet Cordero-Vasallo 1 ORCID, Yusmel Rivero-Yi 1, Odalys González-Dias 2, Hugo Nodarse-Cuni 2, Rafael Machado-Martínez 1 ORCID, Miguel A. Blanco-González 1 ORCID, Julio Valdivia-Arencibia 1, Daymiris Mendez-Felipe 1, Ernesto Delgado-Almora 1, Carlos Gutiérrez-Gutiérrez 1, Juliette Suárez-López 3 ORCID, Jorge L. Leiva-Torres 1, Alicia Rodríguez-Sotolongo 1, Nilda Bejerano-Gil 1

Cited by CrossRef: 6

1- Bezdieniezhnykh N, Lykhova O, Borshchevskiy G, Kruglov Y, Borshchevska M. Evaluation of the duration of new nasal drug interferon α-2b activity in an experimental model system. Virol J. 2025;22(1) [Crossref]
2- Ma Y, Zhou Y, Jiang D, Dai W, Li J, Deng C, Chen C, Zheng G, Zhang Y, Qiu F, Sun H, Xing S, Han H, Qu J, Wu N, Yao Y, Su J. Integration of human organoids single‐cell transcriptomic profiles and human genetics repurposes critical cell type‐specific drug targets for severe COVID‐19. Cell Proliferation. 2024;57(3) [Crossref]
3- Karimi Shahri M, Niazkar H, Rad F. COVID‐19 and hematology findings based on the current evidences: A puzzle with many missing pieces. Int J Lab Hematology. 2021;43(2):160 [Crossref]
4- Pereda R, González D, Rivero H, Rivero J, Pérez A, Lopez L, Mezquia N, Venegas R, Betancourt J, Domínguez R, Nodarse H. Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery. Journal of Interferon & Cytokine Research. 2020;40(12):578 [Crossref]